Linee guida AIAC 2010 per la gestione e il trattamento della - Stopfa

68
vention of thromboembolism in atrial fibrilllation:
Stroke Prevention in Atrial Fibrillation
II Study. Lancet 1994;343:687-91.
711. The Atrial Fibrillation Investigators. The
efficacy of aspirin in patients with atrial fibrillation.
Analysis of pooled data from 3 randomized
trials. Arch Intern Med 1997;157:
1237-40.
712. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose
warfarin versus aspirin for preventing
stroke in patients with atrial fibrillation.
Ann Intern Med 2007;147:590-2.
713. Olsson SB; Executive Steering Committee
of the SPORTIF III Investigators. Stroke
prevention with the oral direct thrombin inhibitor
ximelagatran compared with warfarin
in patients with non-valvular atrial fibrillation
(SPORTIF III): randomised controlled
trial. Lancet 2003;362:1691-8.
714. Albers GW, Diener HC, Frison L, et al.;
SPORTIF Executive Steering Committee for
the SPORTIF V Investigators. Ximelagatran vs
warfarin for stroke prevention in patients
with nonvalvular atrial fibrillation: a randomized
trial. JAMA 2005;293:690-8.
715. Connolly SJ, Ezekowitz MD, Yusuf S,
et al.; RE-LY Steering Committee and Investigators.
Dabigatran versus warfarin in patients
with atrial fibrillation. N Engl J Med
2009;361:1139-51.
716. Devereaux PJ, Anderson DR, Gardner
MJ, et al. Differences between perspectives
of physicians and patients on anticoagulation
in patients with atrial fibrillation: observational
study. BMJ 2001;323:1218-22.
717. Manotti C, Moia M, Palareti G, Pengo
V, Ria L, Dettori AG. Effect of computeraided
management on the quality of treatment
in anticoagulated patients: a prospective,
randomized, multicenter trial of
APROAT (Automated Program for Oral Anticoagulant
Treatment). Haematologica
2001;86:1060-70.
718. Ansell J, Hirsh J, Dalen J, et al. Managing
oral anticoagulant therapy. Chest
2001;119(1 Suppl):22S-38S.
719. Chiquette E, Amato MG, Bussey HI.
Comparison of an anticoagulation clinic
with usual medical care: anticoagulation
control, patient outcomes, and health care
costs. Arch Intern Med 1998;158:1641-7.
720. Pengo V, Prisco D, Iliceto S. Gestione
attuale della terapia anticoagulante orale.
Ital Heart J Suppl 2002;3:502-17.
721. Connolly SJ, Pogue J, Hart RG, et al.;
ACTIVE Investigators. Effect of clopidogrel
added to aspirin in patients with atrial fibrillation.
N Engl J Med 2009;360:2066-78.
722. Grimm RA, Leung DY, Black IW, Stewart
WJ, Thomas JD, Klein AL. Left atrial appendage
“stunning” after spontaneous cardioversion
of atrial fibrillation demonstrated
by transesophageal Doppler echocardiography.
Am Heart J 1995;130:174-6.
723. Motoki H, Tomita T, Aizawa K, et al.
Coagulation activity is increased in the left
atria of patients with paroxysmal atrial fibrillation
during the non-paroxysmal period.
G ITAL CARDIOL | VOL 12 | SUPPL 1 AL N 1 2011
A RAVIELE ET AL
Comparison with chronic atrial fibrillation.
Circ J 2009;73:1403-7.
724. Klein AL, Grimm RA, Murray RD, et
al.; Assessment of Cardioversion Using Transesophageal
Echocardiography Investigators.
Use of transesophageal echocardiography
to guide cardioversion in patients with atrial
fibrillation. N Engl J Med 2001;344:1411-20.
725. Mitchell MA, Hughes GS, Ellenbogen
KA, et al. Cardioversion-related stroke rates
in atrial fibrillation and atrial flutter [abstract].
Circulation 1997;96:I-453.
726. Oral H, Chugh A, Ozaydin M, et al.
Risk of thromboembolic events after percutaneous
left atrial radiofrequency ablation of
atrial fibrillation. Circulation 2006;114: 759-
65.
727. Rossillo A, Bonso A, Themistoclakis S,
et al. Role of anticoagulation therapy after
pulmonary vein antrum isolation for atrial
fibrillation treatment. J Cardiovasc Med
2008;9:51-5.
728. Cakulev I, Waldo AL. Do not stop the
warfarin until ... J Am Coll Cardiol 2010;55:
744-6.
729. Popma JJ, Berger P, Ohman EM, Harrington
RA, Grines C, Weitz JI. Antithrombotic
therapy during percutaneous coronary
intervention: the Seventh ACCP Conference
on Antithrombotic and Thrombolytic Therapy.
Chest 2004;126(3 Suppl):576S-599S.
730. Rubboli A, Di Pasquale G. Come e
quando impiegare la duplice antiaggre -
gazione nel paziente in trattamento con anticoagulanti
orali? G Ital Cardiol 2008;9:
745-52.
731. Orford JL, Fasseas P, Melby S, et al.
Safety and efficacy of aspirin, clopidogrel,
and warfarin after coronary stent placement
in patients with an indication for anticoagulation.
Am Heart J 2004;147:463-7.
732. Mattichak SJ, Reed PS, Gallagher MJ,
Boura JA, O’Neill WW, Kahn JK. Evaluation
of safety of warfarin in combination with
antiplatelet therapy for patients treated with
coronary stents for acute myocardial infarction.
J Interv Cardiol 2005;18:163-6.
733. Khurram Z, Chou E, Minutello R, et al.
Combination therapy with aspirin, clopidogrel
and warfarin following coronary stenting
is associated with a significant risk of
bleeding. J Invasive Cardiol 2006;18:162-4.
734. Porter A, Konstantino Y, Iakobishvili Z,
Shachar L, Battler A, Hasdai D. Short-term
triple therapy with aspirin, warfarin, and a
thienopyridine among patients undergoing
percutaneous coronary intervention.
Catheter Cardiovasc Interv 2006;68:56-61.
735. Lip GY, Karpha M. Anticoagulant and
antiplatelet therapy use in patients with
atrial fibrillation undergoing percutaneous
coronary intervention: the need for consensus
and a management guideline. Chest
2006;130:1823-7.
736. Konstantino Y, Iakobishvili Z, Porter A,
et al. Aspirin, warfarin and a thienopyridine
for acute coronary syndromes. Cardiology
2006;105:80-5.
737. DeEugenio D, Kolman L, DeCaro M, et
al. Risk of major bleeding with concomitant
dual antiplatelet therapy after percutaneous
coronary intervention in patients receiving
long-term warfarin therapy. Pharmacotherapy
2007;27:691-6.
738. Rubboli A, Colletta M, Herzfeld J, Sangiorgio
P, Di Pasquale G. Periprocedural and
medium-term antithrombotic strategies in
patients with an indication for long-term
anticoagulation undergoing coronary angiography
and intervention. Coron Artery
Dis 2007;18:193-9.
739. Lip GY, Huber K, Andreotti F, et al.
Antithrombotic management of atrial fibrillation
patients presenting with acute coronary
syndrome and/or undergoing coronary
stenting: executive summary - a Consensus
Document of the European Society of Cardiology
Working Group on Thrombosis, endorsed
by the European Heart Rhythm Association
(EHRA) and the European
Association of Percutaneous Cardiovascular
Interventions (EAPCI). Eur Heart J 2010;
31:1311-8.
740. Rubboli A, Milandri M, Castelvetri C,
Cosmi B. Meta-analysis of trials comparing
oral anticoagulation and aspirin versus dual
antiplatelet therapy after coronary stenting.
Clues for the management of patients with
an indication for long-term anticoagulation
undergoing coronary stenting. Cardiology
2005;104:101-6.
741. Jafri SM. Periprocedural thromboprophylaxis
in patients receiving chronic anticoagulation
therapy. Am Heart J 2004;147:
3-15.
742. Silber S, Albertsson P, Aviles FF, et al.
Guidelines for percutaneous coronary interventions.
The Task Force for Percutaneous
Coronary Interventions of the European Society
of Cardiology. Eur Heart J 2005;26:
804-47.
743. Kovacs MJ, Kearon C, Rodger M, et al.
Single-arm study of bridging therapy with
low-molecular-weight heparin for patients
at risk of arterial embolism who require temporary
interruption of warfarin. Circulation
2004;110:1658-63.
744. Blackshear JL, Odell JA. Appendage
obliteration to reduce stroke in cardiac surgical
patients with atrial fibrillation. Ann
Thorac Surg 1996;61:755-9.
745. Al-Saady NM, Obel OA, Camm AJ.
Left atrial appendage: structure, function,
and role in thromboembolism. Heart
1999;82:547-54.
746. The European Atrial Fibrillation Trial
Study Group. Optimal oral anticoagulant
therapy in patients with nonrheumatic atrial
fibrillation and recent cerebral ischemia. N
Engl J Med 1995;333:5-10.
747. Go AS, Hylek EM, Chang Y, et al. Anticoagulation
therapy for stroke prevention
in atrial fibrillation: how well do randomized
trials translate into clinical practice? JAMA
2003;290:2685-92.
748. Torn M, Bollen WL, van der Meer FJ,